From the journals: MCP
Among cells, communication is key. Silence of the peptide ions, Mapping the estrogen receptor interactome. Read about papers on these topics recently published in the journal Molecular & Cellular Proteomics.
Among cells, communication is key
Effective cell-to-cell communication is a complex crosstalk crucial for forming and maintaining healthy tissues. Events that disrupt these lines of communication can lead to diseases, such as certain cancers and inadequate tissue repair after cardiac arrest. Wei Wu of the Singapore Immunology Network and the Agency for Science, Technology and Research and Jeroen Krijgsveld of the German Cancer Research Center detailed the value of understanding cellular protein secretion and cellular modes of communication in a perspective in the journal Molecular & Cellular Proteomics. Scientists lack a full understanding of the secretome, the repertoire of molecules that facilitate cellular cross talk. Therefore, the authors concluded more research is needed to define all the molecules essential for cellular communication.
The researchers discussed strategies and model systems that are effective in understanding the protein language of cells. Some of these include cellular co-culture approaches, chemical biology tools, protein enrichment and proteomic and computational methods. Moreover, the complexity of studying the secretome is compounded by how different cells secrete proteins into the extracellular space, such as via extracellular vesicles, endoplasmic reticulum–Golgi classical secretion and nonclassical secretion mechanisms. Nonclassically secreted proteins lack signal peptides, which make them difficult to identify using conventional proteomics methods. Krijgsveld and Wu emphasized that the reliability of a given secretome dataset is based on accurate representation. The higher the proportion of annotated secreted proteins using curated database information; the more representative the secretome. The authors noted that cell type, post-translational modifications and experimental conditions all affect the difficulty of studying the secretome.
Silence of the peptide ions
Mass spectrometry, or MS, is a powerful analytical tool, which when used in proteomics, can reveal qualitative and quantitative information about the proteins that make up the proteome. Multiplex proteomics simultaneously analyses and compares multiple proteomes in a single mass spectrometric assay. However, this method produces errors in peptide quantification due to ion interference, a phenomenon that occurs when peptide ions with similar mass as the target peptide are coisolated in the mass spectrometer. This coisolation can lead to a suppression of quantitative differences and to a misinterpretation of the results.
To address these inaccuracies, Moritz Madern of the University of Vienna and a team of researchers developed a computational method based on regression modelling to accurately predict and correct reporter ion interference in any multiplex proteomics dataset. Their work was published in the journal Molecular & Cellular Proteomics. The authors showed that their strategy could lead to improved quantitative accuracy in multiplex proteomics experiments.
Mapping the estrogen receptor interactome
The National Cancer Institute estimates that estrogen receptor, or ER, positive breast cancer accounts for 70% of all human breast cancers. Specific mutations of ERα, one of the main ERs, can disrupt its regulation and lead to cellular oncogenesis and resistance to treatments such as aromatase inhibitors. This class of drugs is one of the most common hormone therapy drugs used to treat Erα+ breast cancers, and they act by limiting tumor oestrogen, a hormone growth factor for ERα+ breast cancer. Understanding how tumor cells regulate ERα expression is key to designing an appropriate treatment plan.
In a recent study, Camilla Rega at the Institute of Cancer Research, London, and a team of researchers used a novel antibody-based proximity labelling, or PL, approach, coupled with mass spectrometry to investigate the ERα protein network, or interactome. This work was published in the journal Molecular & Cellular Proteomics. Using this approach, they detected most of the known ERα protein interactors in breast cancer cells. The authors also identified that several ERα interactors had undergone modifications, such as sumoylation and ubiquitination, which makes them difficult to detect using conventional methods. This antibody-based PL approach may lead to refinement of the chemotherapeutic agents used to treat ERα+ breast cancer.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Does a protein hold the key to Alzheimer’s?
Researchers in Maryland and Massachusetts team up to study how SORL1 promotes tau trafficking and seeding in cells that leads to the neurodegenerative disorder.
Cracking the recipe for perfect plant-based eggs
It involves finding just the right proteins. With new ingredients and processes, the next generation of substitutes will be not just more egg-like, but potentially more nutritious.
MSU researchers leverage cryo-EM for decades-in-the-making breakthrough
Lee Kroos and Ben Orlando have reported the first high-resolution experimentally determined structures of the intramembrane protease SpolVFB.
From the Journals: MCP
Rapid and precise SARS-CoV-2 detection using mass spec. Mapping brain changes from drug addiction. Decoding plant osmotic stress response. Read about recent MCP papers on these topics.
What seems dead may not be dead
Vincent Tagliabracci will receive the Earl and Thressa Stadtman Distinguished Scientist Award at the ASBMB Annual Meeting, April 12–15 in Chicago.
'You can't afford to be 15 years behind the parasite'
David Fidock will receive the Alice and C.C. Wang Award in Molecular Parasitology at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.